Tags

Type your tag names separated by a space and hit enter

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.
Br J Pharmacol. 2020 11; 177(21):4851-4865.BJ

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 infections has led to a substantial unmet need for treatments, many of which will require testing in appropriate animal models of this disease. Vaccine trials are already underway, but there remains an urgent need to find other therapeutic approaches to either target SARS-CoV-2 or the complications arising from viral infection, particularly the dysregulated immune response and systemic complications which have been associated with progression to severe COVID-19. At the time of writing, in vivo studies of SARS-CoV-2 infection have been described using macaques, cats, ferrets, hamsters, and transgenic mice expressing human angiotensin I converting enzyme 2 (ACE2). These infection models have already been useful for studies of transmission and immunity, but to date only partly model the mechanisms involved in human severe COVID-19. There is therefore an urgent need for development of animal models for improved evaluation of efficacy of drugs identified as having potential in the treatment of severe COVID-19. These models need to reproduce the key mechanisms of COVID-19 severe acute respiratory distress syndrome and the immunopathology and systemic sequelae associated with this disease. Here, we review the current models of SARS-CoV-2 infection and COVID-19-related disease mechanisms and suggest ways in which animal models can be adapted to increase their usefulness in research into COVID-19 pathogenesis and for assessing potential treatments. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Department of Medicine, UCSF, San Francisco, CA, USA.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. Covance Laboratories Limited, Huntingdon, UK.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.Department of Medicine, UCSF, San Francisco, CA, USA.Department of Medicine, UCSF, San Francisco, CA, USA.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. National Institute for Biological Standards and Control, Herts, UK.Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32462701

Citation

Cleary, Simon J., et al. "Animal Models of Mechanisms of SARS-CoV-2 Infection and COVID-19 Pathology." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4851-4865.
Cleary SJ, Pitchford SC, Amison RT, et al. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br J Pharmacol. 2020;177(21):4851-4865.
Cleary, S. J., Pitchford, S. C., Amison, R. T., Carrington, R., Robaina Cabrera, C. L., Magnen, M., Looney, M. R., Gray, E., & Page, C. P. (2020). Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. British Journal of Pharmacology, 177(21), 4851-4865. https://doi.org/10.1111/bph.15143
Cleary SJ, et al. Animal Models of Mechanisms of SARS-CoV-2 Infection and COVID-19 Pathology. Br J Pharmacol. 2020;177(21):4851-4865. PubMed PMID: 32462701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. AU - Cleary,Simon J, AU - Pitchford,Simon C, AU - Amison,Richard T, AU - Carrington,Robert, AU - Robaina Cabrera,C Lorena, AU - Magnen,Mélia, AU - Looney,Mark R, AU - Gray,Elaine, AU - Page,Clive P, Y1 - 2020/07/19/ PY - 2020/04/30/received PY - 2020/05/08/revised PY - 2020/05/11/accepted PY - 2020/5/29/pubmed PY - 2020/10/28/medline PY - 2020/5/29/entrez SP - 4851 EP - 4865 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 infections has led to a substantial unmet need for treatments, many of which will require testing in appropriate animal models of this disease. Vaccine trials are already underway, but there remains an urgent need to find other therapeutic approaches to either target SARS-CoV-2 or the complications arising from viral infection, particularly the dysregulated immune response and systemic complications which have been associated with progression to severe COVID-19. At the time of writing, in vivo studies of SARS-CoV-2 infection have been described using macaques, cats, ferrets, hamsters, and transgenic mice expressing human angiotensin I converting enzyme 2 (ACE2). These infection models have already been useful for studies of transmission and immunity, but to date only partly model the mechanisms involved in human severe COVID-19. There is therefore an urgent need for development of animal models for improved evaluation of efficacy of drugs identified as having potential in the treatment of severe COVID-19. These models need to reproduce the key mechanisms of COVID-19 severe acute respiratory distress syndrome and the immunopathology and systemic sequelae associated with this disease. Here, we review the current models of SARS-CoV-2 infection and COVID-19-related disease mechanisms and suggest ways in which animal models can be adapted to increase their usefulness in research into COVID-19 pathogenesis and for assessing potential treatments. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32462701/Animal_models_of_mechanisms_of_SARS_CoV_2_infection_and_COVID_19_pathology_ L2 - https://doi.org/10.1111/bph.15143 DB - PRIME DP - Unbound Medicine ER -